Day: September 2, 2024

Hepsor V7 OÜ, a subsidiary of Hepsor AS, acquired a property in the heart of Tallinn, at Võistluse 7, where it is planned to build a unique environmentally friendly wooden apartment building. A four-story apartment building is planned for development. The project is based on the sLender-type apartment building concept created by researchers and architects from the Estonian Academy of Arts, inspired by the early 20th-century Lender wooden house style. The building will be constructed entirely from wood, except for the stairwell in the center. The project focuses on environmental protection and includes green technological solutions that enhance climate resilience. “Hepsor is committed to creating innovative and sustainable solutions, building unique and high-quality residential and commercial buildings. The construction of Estonia’s...

Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Biosciences (‘Neurocrine’), triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia, as announced on 28 August 2024. Receipt of the US$35 million payment will be recognized as one-time revenue in the third quarter of 2024. The NBI-’568-SCZ2028 dose-finding study met its primary endpoint for the once-daily 20 mg dose and was generally safe and well tolerated at all doses studied, supporting Neurocrine’s intentions to advance NBI-‘568 into Phase 3 clinical trials in early 2025. Please refer to “Nxera Pharma Notes Positive Phase 2 Data for Partnered...